Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

2.090 +0.180 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 496,015
Open 1.910
Bid (Size) 2.000 (2)
Ask (Size) 2.200 (1)
Prev. Close 1.910
Today's Range 1.910 - 2.190
52wk Range 0.5120 - 2.600
Shares Outstanding 23,228,941
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads
NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads 
Via News Direct
Topics Regulatory Compliance
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy rating. 
Via Benzinga

Performance

YTD
+81.7%
+81.7%
1 Month
+16.8%
+16.8%
3 Month
+115.5%
+115.5%
6 Month
+72.7%
+72.7%
1 Year
+81.8%
+81.8%

More News

Read More
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
Via Benzinga
NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement
Via News Direct
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
From Market News Alerts
Via Business Wire
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
Via News Direct
Topics Regulatory Compliance
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
From PESG Research
Via Business Wire
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
Via Benzinga
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
Via News Direct
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
Via Benzinga
NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Via Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
US Stocks Higher; Private Payrolls Rise By 103,000 In November
Via Benzinga
Topics Stocks
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
Via ACCESSWIRE
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga

Frequently Asked Questions

Is NeuroSense Therapeutics Ltd. - Ordinary Shares publicly traded?
Yes, NeuroSense Therapeutics Ltd. - Ordinary Shares is publicly traded.
What exchange does NeuroSense Therapeutics Ltd. - Ordinary Shares trade on?
NeuroSense Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares?
The ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares is NRSN on the Nasdaq Stock Market
What is the current price of NeuroSense Therapeutics Ltd. - Ordinary Shares?
The current price of NeuroSense Therapeutics Ltd. - Ordinary Shares is 2.090
When was NeuroSense Therapeutics Ltd. - Ordinary Shares last traded?
The last trade of NeuroSense Therapeutics Ltd. - Ordinary Shares was at 07/07/25 04:00 PM ET
What is the market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares?
The market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares is 48.55M
How many shares of NeuroSense Therapeutics Ltd. - Ordinary Shares are outstanding?
NeuroSense Therapeutics Ltd. - Ordinary Shares has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.